Manifestations of Pregabalin Withdrawal

Àlex,; Hamlyn, ra; Foo, Kalvin; Bhatia, Anum; Bobrin, Bradford

doi:10.4172/2378-5756.1000418

Cited by 2 publications

(3 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For the years 1999 and 2019, a total of 46 reports containing 305 cases who developed MDs after the use of PGB from 17 different countries were reported [ Table 1 ]. [ 2 3 10 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 ] The origin was North American in 196, European in 68, Asian in 40, and South American in 1. The MDs associated with PGB found were as follows: 184 patients with ataxia, 61 with tremors, 39 with MCL, 8 with parkinsonism, 1 with restless legs syndrome, 1 with dystonia, 1 with dyskinesia, and 1 with akathisia.…”

Section: Resultsmentioning

confidence: 99%

“…described a male taking PGB that stopped the medication abruptly without medical advice, and after 1 week, the patient started with akathisia; when the drug was reintroduced, the patient symptoms improved. [ 28 ] In this way, both cases are contradictory: in one, the akathisia was caused by an increase of PGB and, in the other, by the decrease of PGB. We can assume, in the same way as with MCL, that the changes of PGB concentration in predisposed individuals may lead to increased or decreased inhibition in the internal and external globus pallidus.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Pregabalin-associated movement disorders: A literature review

Rissardo

Caprara

2020

Brain Circ

View full text Add to dashboard Cite

Central nervous system adverse effects are commonly reported with pregabalin (PGB). On the other hand, movement disorders (MDs) associated with this drug were rarely described. However, their occurrence could significantly affect the quality of life of PGB users. This literature review aims to evaluate the clinical epidemiological profile, pathological mechanisms, and management of PGB-associated MDs. Relevant reports in six databases were identified and assessed by two reviewers without language restriction. A total of 46 reports containing 305 cases from 17 countries were assessed. The MDs encountered were as follows: 184 individuals with ataxia, 61 with tremors, 39 with myoclonus, 8 with parkinsonism, 1 with restless legs syndrome, 1 with dystonia, 1 with dyskinesia, and 1 with akathisia. The mean age was 62 years (range: 23–94). The male sex was slightly predominant with 54.34%. The mean PGB dose when the MD occurred was 238 mg, and neuropathic pain was the most common indication of PGB. The time from PGB start to MD was < 1 month at 75%. The time from PGB withdrawal to recovery was < 1 week at 77%. All the individuals where the follow-up was reported had a full recovery. The most common management was PGB withdrawal. In the literature, the majority of the cases did not report information about timeline events, neurological examination details, or electrodiagnostic studies. The best management for all MDs is probably PGB withdrawal. If the patient is on dialysis program, perhaps an increased number of sessions will decrease recovery time. Furthermore, the addition of a benzodiazepine could accelerate recovery.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Pregabalin-associated movement disorders: A literature review

Rissardo

Caprara

2020

Brain Circ

View full text Add to dashboard Cite

show abstract

“…[12][13][14] It may lead to unnecessary dose escalation and/or additional treatment to control symptoms, itself resulting in the onset of avoidable side-effects. [15][16][17][18][19] Nonadherence may also result in adverse events related to discontinuation [20][21][22] or re-initiation. 23,24 Furthermore, increased expenditure is incurred through preventable unscheduled primary and secondary care engagement (including primary care consultations and emergency department presentation), and wasted medication.…”

Section: Introductionmentioning

confidence: 99%

Measuring and reporting treatment adherence: What can we learn by comparing two respiratory conditions?

Tibble

Flook

Sheikh

et al. 2020

Brit J Clinical Pharma

View full text Add to dashboard Cite

Medication non-adherence, defined as any deviation from the regimen recommended by their healthcare provider, can increase morbidity, mortality and side effects, while reducing effectiveness. Through studying two respiratory conditions, asthma and tuberculosis (TB), we thoroughly review the current understanding of the measurement and reporting of medication adherence. In this paper, we identify major meth

show abstract

Manifestations of Pregabalin Withdrawal

Cited by 2 publications

References 7 publications

Pregabalin-associated movement disorders: A literature review

Pregabalin-associated movement disorders: A literature review

Measuring and reporting treatment adherence: What can we learn by comparing two respiratory conditions?

Contact Info

Product

Resources

About